ORASIS PHARMACEUTICALS Announces the FDA Approval of QLOSI™
“I am grateful to the Orasis team, our strategic partners, clinical investigators, and patients who participated in our clinical trials, all of whom made this achievement possible.” said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals.
Orasis announces the FDA approval of QLOSI, a treatment to alleviate the symptoms of Presbyopia.